EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Continuous topical application of microencapsulated recombinant human epidermal growth factor does not promote the progression of established melanoma in animals

Chien-Shan Wu, Jian-Ching Wu, Ching-Min Tseng, Le-Shin Chang, Chi-Fang Wu, Yi-Tzu Li, Yi-Wen Lin, Ming-Hong Tai

Gene & Protein in Disease · 2023

DOI: 10.36922/gpd.1848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gene & Protein in Disease, 2023. Verfasst von Chien-Shan Wu und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microencapsulated epidermal growth factor (EGF) device has been applied topically for the management of several types of wounds to accelerate wound healing and prevent scar formation. However, it remains unclear whether such EGF device induced neoplastic transformation in the skin. In this study, we exploited a well-established murine B16-F10 melanoma model, coupled with MTT viability and colony formation assays, to investigate the influence of microencapsulated recombinant EGF (Me-EGF; brand name NewEpi®) and its ingredients on the tumorigenicity of skin cancer cells in vitro and in vivo. The results indicated that Me-EGF did not stimulate the viability nor the anchorage-dependent growth of B16-F10 melanoma cells. Western blot analysis showed that Me-EGF treatment increased the total and phosphorylated EGFR expression without affecting the HER2 expression in B16-F10 melanoma cells. In mice bearing established B16-F10 melanoma, continuous application of Me-EGF for 14 days did not enhance the melanoma tumor burden compared with control groups. Immunohistochemical analysis also revealed the similar expression of proliferative index Ki-67 between Me-EGF-treated melanoma and other groups. Altogether, these results suggest that the application of Me-EGF device did not promote the oncogenic potential of B16-F10 melanoma in vitro and in vivo.

Zitieren

APA

Wu, C., Wu, J., Tseng, C., Chang, L., Wu, C., Li, Y., Lin, Y., & Tai, M. (2023). Continuous topical application of microencapsulated recombinant human epidermal growth factor does not promote the progression of established melanoma in animals. Gene & Protein in Disease. https://doi.org/10.36922/gpd.1848

Vancouver

Wu C, Wu J, Tseng C, Chang L, Wu C, Li Y, et al. Continuous topical application of microencapsulated recombinant human epidermal growth factor does not promote the progression of established melanoma in animals. Gene & Protein in Disease. 2023. doi:10.36922/gpd.1848

BibTeX
@article{Wu2023,
  author = {Wu, Chien-Shan and Wu, Jian-Ching and Tseng, Ching-Min and Chang, Le-Shin and Wu, Chi-Fang and Li, Yi-Tzu and Lin, Yi-Wen and Tai, Ming-Hong},
  title = {Continuous topical application of microencapsulated recombinant human epidermal growth factor does not promote the progression of established melanoma in animals},
  journal = {Gene & Protein in Disease},
  year = {2023},
  doi = {10.36922/gpd.1848}
}
Kostenlos starten →